In January 2018, Mirati and Beigene announced an exclusive license agreement for the development, manufacturing and commercialization of Mirati’s sitravatinib in Asia (excluding Japan), Australia, and New Zealand. Mirati retained exclusive rights for the development, manufacturing and commercialization of sitravatinib for the rest of world.
Mirati is eligible to receive milestone payments based upon the achievement of certain development, regulatory and sales milestones as well as significant royalties on future sales of sitravatinib in the licensed territory.
In January 2019, Mirati and Bristol-Myers Squibb Company (BMY) announced a clinical collaboration to evaluate the combination of sitravatinib and nivolumab (OPDIVO®), in a Phase 3 trial in second line non-small cell lung cancer (NSCLC) patients who have progressed following treatment with a platinum-based regimen and a checkpoint inhibitor.
Under the terms of the collaboration, Mirati will sponsor and fund the clinical trial and Bristol-Myers Squibb will provide nivolumab at no cost. Mirati maintains global development and commercial rights to sitravatinib outside of certain Asian territories, where it is partnered with BeiGene, and is free to develop the program in combination with other agents.
In July 2019, Mirati and Novartis (NVS) announced a clinical collaboration agreement to evaluate the combination of MRTX849, Mirati’s investigational KRAS G12C inhibitor and TNO155, Novartis’ investigational SHP2 inhibitor, in patients with advanced solid tumors that harbor KRAS G12C mutations.
Under terms of the non-exclusive collaboration, Mirati will sponsor the trial and Novartis and Mirati will jointly oversee and share the costs of clinical development activities for the combined therapy. Novartis will provide TNO155 at no cost.
In September 2020, Mirati and Boehringer Ingelheim announced a clinical collaboration to evaluate the combination of BI 1701963, a SOS1::pan-KRAS inhibitor, and MRTX849, a KRAS G12C selective inhibitor in patients with solid tumors that harbor the KRAS G12C mutation.
Under the terms of the non-exclusive collaboration, Mirati will be the sponsor of the trial and Boehringer Ingelheim and Mirati will jointly share the costs of and oversee clinical development for the combined therapy.